Učitavanje...
Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?
Phase-I trials traditionally involve dose-escalation to determine the maximal tolerated dose (MTD). With conventional chemotherapy, efficacy is generally deemed to be dose-dependent, but the same may not be applicable to molecularly targeted agents (MTAs). We analysed consecutive patients included i...
Spremljeno u:
| Glavni autori: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Nature Publishing Group
2009
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2694416/ https://ncbi.nlm.nih.gov/pubmed/19401696 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605030 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|